pentobarbital will lower the extent or effect of artemether/lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration with strong CYP3A4 inducers may lead to diminished serum concentrations and loss of antimalarial efficacy

pentobarbital and olopatadine intranasal each improve sedation. Avoid or Use Alternate Drug. Coadministration boosts danger of CNS despair, which can result in additive impairment of psychomotor general performance and bring about daytime impairment.

pentobarbital will decrease the level or outcome of prednisone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will reduce the level or effect of sildenafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Potent CYP3A4 inducers are expected to induce significant decreases in sildenafil plasma stages

pentobarbital will minimize the extent or impact of ripretinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

Slight (one)pentobarbital will decrease the level or result of paclitaxel protein certain by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Mysterious.

pentobarbital will minimize the extent or impact of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.

Keep track of Closely (1)pentobarbital will decrease the level or check here influence of cannabidiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will minimize the level or influence of etonogestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

pentobarbital will lessen the extent or effect of diclofenac by impacting hepatic enzyme CYP2C9/ten metabolism. Slight/Importance Not known.

Keep an eye on Carefully (1)pentobarbital will minimize the level or result of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to some decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome inside a patient who may have designed physical dependence to fentanyl. After halting a CYP3A4 inducer, since the effects from the inducer drop, the fentanyl plasma concentration will raise which could improve or prolong both of those the therapeutic and adverse effects.

pentobarbital will decrease the extent or result of paclitaxel protein bound by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.

pentobarbital will minimize the extent or result of lefamulin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Steer clear of coadministration of lefamulin with robust or reasonable CYP3A inducers Until the gain outweighs threats. Monitor for minimized efficacy.

pentobarbital will lessen the level or impact of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.